Filing Details

Accession Number:
0001209191-22-046880
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-19 17:16:36
Reporting Period:
2022-08-17
Accepted Time:
2022-08-19 17:16:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1348911 Kalvista Pharmaceuticals Inc. KALV Pharmaceutical Preparations (2834) 200915291
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1691102 Christopher Yea C/O Kalvista Pharmaceuticals, Inc
55 Cambridge Parkway, Suite 901E
Cambridge MA 02142
Chief Development Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-08-17 1,773 $0.00 34,742 No 4 M Direct
Common Stock Disposition 2022-08-17 1,145 $14.96 33,597 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Disposition 2022-08-17 1,773 $0.00 1,773 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
26,607 No 4 M Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
  2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.96 to $15.0249, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  4. 1/16th of the total restricted stock units subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, subject to continued service through each vesting date.